TESSERA THERAPEUTICS STOCK PRICE SERIES

Noubar Afeyan, Ph.D., is Co-Founder and Chairman of Tessera Therapeutics and Founder and CEO of Flagship Pioneering. Its research engine further optimizes the discovered candidates for efficiency, specificity, and fidelity-essentially compressing eons of evolution into a few months. The company has evaluated tens of thousands of natural and synthetic MGEs to create candidates with the ability to write therapeutic messages into the human genome. Tessera’s gene writer tools are based on nature’s genome architects, Mobile Genetic Elements (MGEs)-the most abundant class of genes across the tree of life, representing approximately half of the human genome. Gene Writing holds the potential to become a. Latest Financing Round Will Support Tessera’s Build Out of its GENE WRITING Platforms and Pursuit of Multiple Therapeutic Programs for Clinical Development. Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source.

TESSERA THERAPEUTICS STOCK PRICE SERIES

The platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics Announces Over 300M Series C Financing to Advance its GENE WRITING Platform. Led by Geoffrey von Maltzahn, Ph.D., Co-Founder, Chief Executive Officer, and Board Director, Tessera Therapeutics provides gene writing technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. Tessara’s RealBrain technology manufactured 3D human mimetic brain tissue has near-market. The company's technology help scientists and clinicians with the ability to write small and large therapeutic messages into the genome to treat diseases at their source, enabling healthcare providers to cure their patients and improve. The company intends to use the funds to expand its development efforts. Tessara Therapeutics Pty Ltd, a Melbourne-based biotechnology company developing human mimetic tissues, has closed its Round 1 capital raising in the amount of 2.7 million, significantly over-subscribed. Developer of gene writing technology designed to permanently make small and large alterations to the human genome. Investors included Abu Dhabi Investment Authority (ADIA), Alaska Permanent Fund Corporation, Altitude Life Science Ventures, ARTIS Ventures, Cormorant Asset Management, Flagship Pioneering, Hanwha Impact Partners, Longevity Vision Fund, March Capital, SALT Fund, SoftBank Vision Fund 2, and T. Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to. Tessera Therapeutics, a Somerville, MA-based biotechnology company, raised over $300M in Series C funding.

Tessera therapeutics stock price